Regenxbio (RGNX) Cash from Investing Activities (2015 - 2025)

Regenxbio's Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $37.5 million for Q4 2025.

• In Q4 2025, Cash from Investing Activities fell 6.79% year-over-year to $37.5 million; the TTM figure through Dec 2025 stood at -$15.9 million (down 115.34% YoY), while the FY2025 annual figure was -$15.9 million, down 115.34% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at $37.5 million, down from $42.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $63.1 million in Q1 2023, with the low at -$216.4 million in Q4 2021.
• The 5-year median for Cash from Investing Activities is $30.3 million (2022), against an average of -$7.0 million.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities jumped 5208.05% in 2023, then tumbled 52301.49% in 2025.
• Regenxbio's Cash from Investing Activities stood at -$216.4 million in 2021, then jumped by 112.34% to $26.7 million in 2022, then climbed by 27.24% to $34.0 million in 2023, then rose by 18.54% to $40.3 million in 2024, then declined by 6.79% to $37.5 million in 2025.
• Business Quant data shows RGNX's Cash from Investing Activities at $37.5 million in Q4 2025, $42.3 million in Q3 2025, and -$140.4 million in Q2 2025.